دورية أكاديمية
Electronic cigarettes for smoking cessation.
| العنوان: | Electronic cigarettes for smoking cessation. |
|---|---|
| المؤلفون: | Lindson N; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Butler AR; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., McRobbie H; National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia., Bullen C; National Institute for Health Innovation, University of Auckland, Auckland, New Zealand., Hajek P; Wolfson Institute of Preventive Medicine, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, London, UK., Begh R; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Theodoulou A; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Notley C; Norwich Medical School, University of East Anglia, Norwich, UK., Rigotti NA; Tobacco Research and Treatment Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Turner T; Cochrane Australia, School of Public Health & Preventive Medicine, Monash University, Melbourne, Australia., Livingstone-Banks J; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Morris T; Department of Population Health Sciences, University of Leicester, Leicester, UK., Hartmann-Boyce J; Department of Health Promotion and Policy, University of Massachusetts, Amherst, MA, USA. |
| المصدر: | The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2024 Jan 08; Vol. 1. Cochrane AN: CD010216. Date of Electronic Publication: 2024 Jan 08. |
| نوع المنشور: | Journal Article; Meta-Analysis; Systematic Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2004- : Chichester, West Sussex, England : Wiley Original Publication: Oxford, U.K. ; Vista, CA : Update Software, |
| مواضيع طبية MeSH: | Electronic Nicotine Delivery Systems* , Smoking Cessation*, Humans ; Nicotine/adverse effects ; Nicotine Replacement Therapy ; Randomized Controlled Trials as Topic ; Network Meta-Analysis |
| مستخلص: | Background: Electronic cigarettes (ECs) are handheld electronic vaping devices which produce an aerosol by heating an e-liquid. People who smoke, healthcare providers and regulators want to know if ECs can help people quit smoking, and if they are safe to use for this purpose. This is a review update conducted as part of a living systematic review. Objectives: To examine the safety, tolerability and effectiveness of using electronic cigarettes (ECs) to help people who smoke tobacco achieve long-term smoking abstinence, in comparison to non-nicotine EC, other smoking cessation treatments and no treatment. Search Methods: We searched the Cochrane Tobacco Addiction Group's Specialized Register to 1 February 2023, and Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and PsycINFO to 1 July 2023, and reference-checked and contacted study authors. Selection Criteria: We included trials in which people who smoke were randomized to an EC or control condition. We also included uncontrolled intervention studies in which all participants received an EC intervention as these studies have the potential to provide further information on harms and longer-term use. Studies had to report an eligible outcome. Data Collection and Analysis: We followed standard Cochrane methods for screening and data extraction. Critical outcomes were abstinence from smoking after at least six months, adverse events (AEs), and serious adverse events (SAEs). We used a fixed-effect Mantel-Haenszel model to calculate risk ratios (RRs) with a 95% confidence interval (CI) for dichotomous outcomes. For continuous outcomes, we calculated mean differences. Where appropriate, we pooled data in pairwise and network meta-analyses (NMA). Main Results: We included 88 completed studies (10 new to this update), representing 27,235 participants, of which 47 were randomized controlled trials (RCTs). Of the included studies, we rated ten (all but one contributing to our main comparisons) at low risk of bias overall, 58 at high risk overall (including all non-randomized studies), and the remainder at unclear risk. There is high certainty that nicotine EC increases quit rates compared to nicotine replacement therapy (NRT) (RR 1.59, 95% CI 1.29 to 1.93; I 2 = 0%; 7 studies, 2544 participants). In absolute terms, this might translate to an additional four quitters per 100 (95% CI 2 to 6 more). There is moderate-certainty evidence (limited by imprecision) that the rate of occurrence of AEs is similar between groups (RR 1.03, 95% CI 0.91 to 1.17; I 2 = 0%; 5 studies, 2052 participants). SAEs were rare, and there is insufficient evidence to determine whether rates differ between groups due to very serious imprecision (RR 1.20, 95% CI 0.90 to 1.60; I 2 = 32%; 6 studies, 2761 participants; low-certainty evidence). There is moderate-certainty evidence, limited by imprecision, that nicotine EC increases quit rates compared to non-nicotine EC (RR 1.46, 95% CI 1.09 to 1.96; I 2 = 4%; 6 studies, 1613 participants). In absolute terms, this might lead to an additional three quitters per 100 (95% CI 1 to 7 more). There is moderate-certainty evidence of no difference in the rate of AEs between these groups (RR 1.01, 95% CI 0.91 to 1.11; I 2 = 0%; 5 studies, 1840 participants). There is insufficient evidence to determine whether rates of SAEs differ between groups, due to very serious imprecision (RR 1.00, 95% CI 0.56 to 1.79; I 2 = 0%; 9 studies, 1412 participants; low-certainty evidence). Due to issues with risk of bias, there is low-certainty evidence that, compared to behavioural support only/no support, quit rates may be higher for participants randomized to nicotine EC (RR 1.88, 95% CI 1.56 to 2.25; I 2 = 0%; 9 studies, 5024 participants). In absolute terms, this represents an additional four quitters per 100 (95% CI 2 to 5 more). There was some evidence that (non-serious) AEs may be more common in people randomized to nicotine EC (RR 1.22, 95% CI 1.12 to 1.32; I 2 = 41%, low-certainty evidence; 4 studies, 765 participants) and, again, insufficient evidence to determine whether rates of SAEs differed between groups (RR 0.89, 95% CI 0.59 to 1.34; I 2 = 23%; 10 studies, 3263 participants; very low-certainty evidence). Results from the NMA were consistent with those from pairwise meta-analyses for all critical outcomes, and there was no indication of inconsistency within the networks. Data from non-randomized studies were consistent with RCT data. The most commonly reported AEs were throat/mouth irritation, headache, cough, and nausea, which tended to dissipate with continued EC use. Very few studies reported data on other outcomes or comparisons, hence, evidence for these is limited, with CIs often encompassing both clinically significant harm and benefit. Authors' Conclusions: There is high-certainty evidence that ECs with nicotine increase quit rates compared to NRT and moderate-certainty evidence that they increase quit rates compared to ECs without nicotine. Evidence comparing nicotine EC with usual care/no treatment also suggests benefit, but is less certain due to risk of bias inherent in the study design. Confidence intervals were for the most part wide for data on AEs, SAEs and other safety markers, with no difference in AEs between nicotine and non-nicotine ECs nor between nicotine ECs and NRT. Overall incidence of SAEs was low across all study arms. We did not detect evidence of serious harm from nicotine EC, but the longest follow-up was two years and the number of studies was small. The main limitation of the evidence base remains imprecision due to the small number of RCTs, often with low event rates. Further RCTs are underway. To ensure the review continues to provide up-to-date information to decision-makers, this review is a living systematic review. We run searches monthly, with the review updated when relevant new evidence becomes available. Please refer to the Cochrane Database of Systematic Reviews for the review's current status. (Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.) |
| التعليقات: | Update of: Cochrane Database Syst Rev. 2022 Nov 17;11:CD010216. (PMID: 36384212) |
| References: | Addict Behav. 2018 May;80:1-5. (PMID: 29304395) Nicotine Tob Res. 2022 Jun 15;24(7):1079-1088. (PMID: 34929031) Regul Toxicol Pharmacol. 2015 Apr;71(3):498-506. (PMID: 25683775) Curr Hypertens Rep. 2020 Nov 23;23(1):2. (PMID: 33230755) Addict Behav. 2020 Apr;103:106222. (PMID: 31838445) Addiction. 2012 Oct;107(10):1857-67. (PMID: 22594651) Nicotine Tob Res. 2021 Jun 8;23(7):1113-1122. (PMID: 33723598) Lancet. 2013 Nov 16;382(9905):1629-37. (PMID: 24029165) Curr Probl Cardiol. 2023 Sep;48(9):101748. (PMID: 37088177) Ann Am Thorac Soc. 2019 Feb;16(2):280-282. (PMID: 30290121) Psychopharmacology (Berl). 2006 Mar;184(3-4):274-85. (PMID: 16362402) Addiction. 2021 May;116(5):985-993. (PMID: 32364274) Addict Behav Rep. 2019 Jul 03;10:100202. (PMID: 31338412) Contemp Clin Trials Commun. 2020 Jan 08;17:100518. (PMID: 31956726) JAMA Netw Open. 2020 Jan 3;3(1):e1920255. (PMID: 32003818) J Dual Diagn. 2019 Jul-Sep;15(3):184-191. (PMID: 31169077) Addiction. 2020 Jun;115(6):1141-1148. (PMID: 31994254) PeerJ. 2018 Sep 28;6:e5609. (PMID: 30280019) Nicotine Tob Res. 2014 Jun;16(6):672-81. (PMID: 24376276) JAMA. 2021 Jan 19;325(3):280-298. (PMID: 33464342) Eur J Prev Cardiol. 2023 Mar 27;30(5):425-435. (PMID: 36316290) Lancet Respir Med. 2021 Aug;9(8):840-850. (PMID: 33857436) JMIR Res Protoc. 2016 Feb 03;5(1):e21. (PMID: 26842790) Nicotine Tob Res. 2022 Jun 15;24(7):955-961. (PMID: 34850164) Nicotine Tob Res. 2015 Apr;17(4):473-8. (PMID: 25762758) J Dual Diagn. 2018 Jan-Mar;14(1):2-13. (PMID: 29083287) Addict Sci Clin Pract. 2013 Mar 05;8:5. (PMID: 23497603) Nicotine Tob Res. 2019 Aug 19;21(9):1259-1266. (PMID: 30203076) Am J Health Behav. 2014 Mar;38(2):265-74. (PMID: 24629555) Nicotine Tob Res. 2015 Feb;17(2):175-9. (PMID: 25122503) Am J Prev Med. 2016 Sep;51(3):356-63. (PMID: 27005984) JMIR Public Health Surveill. 2023 Apr 4;9:e42628. (PMID: 37014673) JAMA Netw Open. 2019 Nov 1;2(11):e1915494. (PMID: 31730180) Br Dent J. 2016 Dec 9;221(11):722-726. (PMID: 27932811) Pharmacol Biochem Behav. 1996 Feb;53(2):309-15. (PMID: 8808137) Ther Adv Drug Saf. 2014 Apr;5(2):67-86. (PMID: 25083263) Nicotine Tob Res. 2016 May;18(5):1134-41. (PMID: 26045250) Tob Regul Sci. 2016 Oct;2(4):352-362. (PMID: 27942543) Drug Alcohol Depend. 1994 Feb;34(3):225-9. (PMID: 8033760) Int J Environ Res Public Health. 2015 Jul 08;12(7):7638-46. (PMID: 26184244) Tob Control. 2019 Mar;28(2):146-151. (PMID: 29853561) Addiction. 2013 Jun;108(6):1115-25. (PMID: 23551515) N Engl J Med. 2018 Jun 14;378(24):2302-2310. (PMID: 29791259) Nicotine Tob Res. 2021 Mar 19;23(4):625-634. (PMID: 32939543) Int J Environ Res Public Health. 2015 Mar 24;12(4):3428-38. (PMID: 25811767) PLoS One. 2019 Jul 25;14(7):e0220300. (PMID: 31344110) Health Technol Assess. 2019 Aug;23(43):1-82. (PMID: 31434605) Nicotine Tob Res. 2023 Feb 9;25(3):395-403. (PMID: 35738868) Res Synth Methods. 2019 Dec;10(4):569-581. (PMID: 31349391) Nat Med. 2023 Nov;29(11):2957. (PMID: 36344702) Addict Behav. 2016 Aug;59:30-4. (PMID: 27043170) Nicotine Tob Res. 2022 Jun 15;24(7):1047-1054. (PMID: 35134961) PLoS One. 2013 Jun 24;8(6):e66317. (PMID: 23826093) Nicotine Tob Res. 2021 Oct 7;23(11):1972-1976. (PMID: 33837422) Psychol Med. 2019 Apr;49(6):1033-1040. (PMID: 29986786) Trials. 2019 Nov 28;20(1):659. (PMID: 31779689) Sci Rep. 2020 Apr 30;10(1):7322. (PMID: 32355323) Trials. 2014 Mar 22;15:88. (PMID: 24655473) Nicotine Tob Res. 2016 Apr;18(4):501-7. (PMID: 25895951) Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1945-53. (PMID: 20647410) Pharmacol Biochem Behav. 2000 Sep;67(1):71-81. (PMID: 11113486) Int J Drug Policy. 2017 Jun;44:84-85. (PMID: 28454011) Contemp Clin Trials. 2017 Sep;60:56-62. (PMID: 28648969) Clin Pharmacokinet. 2001;40(9):661-84. (PMID: 11605715) Tob Prev Cessat. 2021 Nov 22;7:69. (PMID: 34877438) J Addict Med. 2022 May-Jun 01;16(3):272-277. (PMID: 34128486) AIDS Behav. 2023 Feb;27(2):618-627. (PMID: 35869375) BMC Public Health. 2017 Apr 4;17(1):293. (PMID: 28376818) Int J Environ Res Public Health. 2016 Mar 04;13(3):. (PMID: 26959042) Regul Toxicol Pharmacol. 2018 Feb;92:226-238. (PMID: 29248487) Harm Reduct J. 2020 Oct 12;17(1):73. (PMID: 33046080) Psychopharmacology (Berl). 2016 Aug;233(15-16):2933-41. (PMID: 27235016) Lancet. 2014 Feb 1;383(9915):408-9. (PMID: 24485579) Nicotine Tob Res. 2022 Aug 6;24(9):1448-1457. (PMID: 35430631) Nicotine Tob Res. 1999 Dec;1(4):357-64. (PMID: 11072433) Prev Med. 2022 Dec;165(Pt B):107213. (PMID: 35995103) BMJ Open. 2021 Apr 27;11(4):e045396. (PMID: 33906842) Cochrane Database Syst Rev. 2018 May 31;5:CD000146. (PMID: 29852054) Nicotine Tob Res. 2020 Apr 21;22(5):699-704. (PMID: 30365024) Am J Public Health. 2012 Sep;102(9):1758-66. (PMID: 22813087) Nicotine Tob Res. 2018 Sep 4;20(10):1265-1271. (PMID: 29272446) Nicotine Tob Res. 2014 Jan;16(1):108-14. (PMID: 24154511) Subst Abuse. 2013 Sep 03;7:139-46. (PMID: 24049448) Pilot Feasibility Stud. 2019 Jun 04;5:74. (PMID: 31171977) Contemp Clin Trials Commun. 2019 Jul 19;15:100412. (PMID: 31388599) Chest. 1995 May;107(5):1358-64. (PMID: 7750331) Nicotine Tob Res. 2023 Feb 9;25(3):372-378. (PMID: 35752091) CJC Open. 2020 Mar 19;2(3):168-175. (PMID: 32462131) Addiction. 2023 Nov;118(11):2105-2117. (PMID: 37455014) N Engl J Med. 2015 Oct;373(14):1340-9. (PMID: 26422724) Cochrane Database Syst Rev. 2014;(12):CD010216. (PMID: 25515689) BMC Public Health. 2014 Nov 08;14:1159. (PMID: 25380748) Cochrane Database Syst Rev. 2016 Sep 14;9:CD010216. (PMID: 27622384) Harm Reduct J. 2018 Jun 20;15(1):31. (PMID: 29921278) PLoS One. 2020 Oct 23;15(10):e0240968. (PMID: 33095798) Prev Med. 2022 Dec;165(Pt B):107182. (PMID: 35933001) Cancer Prev Res (Phila). 2015 Sep;8(9):873-8. (PMID: 26333731) N Engl J Med. 2010 Jun 17;362(24):2295-303. (PMID: 20554984) Nicotine Tob Res. 2024 Feb 22;26(3):257-269. (PMID: 37619211) Arch Intern Med. 1999 Sep 27;159(17):2033-8. (PMID: 10510989) Am J Public Health. 2015 Nov;105(11):e1. (PMID: 26270297) Cochrane Database Syst Rev. 2020 Oct 14;10:CD010216. (PMID: 33052602) Drug Alcohol Depend. 2009 Sep 1;104(1-2):23-33. (PMID: 19446968) Circulation. 2018 Jan 16;137(3):303-306. (PMID: 29335291) Addiction. 2014 Nov;109(11):1801-10. (PMID: 25078252) Biol Psychiatry. 2010 Apr 15;67(8):707-14. (PMID: 20132927) BMJ Open. 2021 Jun 30;11(6):e048859. (PMID: 34193499) Intern Emerg Med. 2014 Aug;9(5):537-46. (PMID: 23873169) Nicotine Tob Res. 2013 Jan;15(1):158-66. (PMID: 22529223) Nicotine Tob Res. 2016 Oct;18(10):1937-1943. (PMID: 26783292) BMC Public Health. 2013 Sep 24;13:883. (PMID: 24063569) Addiction. 2023 Mar;118(3):539-545. (PMID: 36208090) Nicotine Tob Res. 2013 Jan;15(1):267-70. (PMID: 22311962) Clin Sci (Lond). 2016 Nov 1;130(21):1929-37. (PMID: 27543458) N Engl J Med. 2020 Feb 20;382(8):697-705. (PMID: 31860793) Pharmacol Biochem Behav. 1985 Aug;23(2):289-93. (PMID: 4059314) Tob Control. 2023 Nov;32(6):786-789. (PMID: 35351805) Behav Med. 2023 Oct-Dec;49(4):392-401. (PMID: 35614523) Am J Med. 2023 Aug;136(8):804-813.e4. (PMID: 37148992) JMIR Res Protoc. 2021 May 14;10(5):e27088. (PMID: 33988520) JAMA Netw Open. 2020 Nov 2;3(11):e2026324. (PMID: 33206193) EClinicalMedicine. 2019 Nov 16;17:100208. (PMID: 31891141) Am J Public Health. 2021 Feb;111(2):230-246. (PMID: 33351653) Health Promot Pract. 2022 May;23(3):388-396. (PMID: 33660555) Addict Behav. 2022 Jan;124:107097. (PMID: 34536632) Regul Toxicol Pharmacol. 2016 Feb;74:193-9. (PMID: 26702788) Cochrane Database Syst Rev. 2019 Apr 18;4:CD013308. (PMID: 30997928) Perspect Public Health. 2020 Nov;140(6):351-361. (PMID: 32389072) Addiction. 2022 May;117(5):1427-1437. (PMID: 34859526) Nicotine Tob Res. 2020 Apr 17;22(4):594-595. (PMID: 30239904) Sci Rep. 2016 Jan 05;6:18763. (PMID: 26729619) Tob Induc Dis. 2021 Jan 13;19:04. (PMID: 33456434) Toxicol Rep. 2021 Jan 27;8:282-294. (PMID: 33552927) Addict Behav. 2021 Aug;119:106912. (PMID: 33798919) Radiology. 2022 Jul;304(1):195-204. (PMID: 35380498) Addiction. 2004 Jan;99(1):29-38. (PMID: 14678060) Nicotine Tob Res. 2022 Jun 15;24(7):994-1002. (PMID: 35022796) JAMA. 2020 Nov 10;324(18):1844-1854. (PMID: 33170240) PLoS One. 2015 Jun 10;10(6):e0129443. (PMID: 26061661) Biology (Basel). 2021 Nov 19;10(11):. (PMID: 34827200) Addiction. 2020 Mar;115(3):507-517. (PMID: 31597207) JAMA. 2021 Jan 19;325(3):265-279. (PMID: 33464343) Nicotine Tob Res. 2016 Aug;18(8):1757-62. (PMID: 26834051) Nicotine Tob Res. 2022 Oct 26;24(11):1811-1820. (PMID: 35575085) Addict Behav. 2021 Jul;118:106909. (PMID: 33756301) Nicotine Tob Res. 2020 Feb 6;22(2):297-301. (PMID: 30500925) Addiction. 2007 Feb;102(2):324-34. (PMID: 17222288) Cancer Prev Res (Phila). 2020 Feb;13(2):145-152. (PMID: 31619441) Intern Emerg Med. 2016 Feb;11(1):85-94. (PMID: 26749533) Nat Med. 2022 May;28(5):958-964. (PMID: 35577966) Food Chem Toxicol. 2020 Jul;141:111389. (PMID: 32343994) BMC Public Health. 2021 Nov 8;21(1):2038. (PMID: 34749706) Regul Toxicol Pharmacol. 2016 Feb;74:187-92. (PMID: 26696273) Nicotine Tob Res. 2018 Jan 5;20(2):206-214. (PMID: 28003511) Addiction. 2011 Nov;106(11):2017-28. (PMID: 21592253) Drug Alcohol Depend. 1993 Oct;33(3):211-23. (PMID: 8261886) Nicotine Tob Res. 2022 Aug 6;24(9):1405-1412. (PMID: 35363874) Addict Behav. 2022 Aug;131:107328. (PMID: 35405479) Eur J Clin Invest. 2016 Aug;46(8):698-706. (PMID: 27322745) Cochrane Database Syst Rev. 2019 Jun 05;6:CD009670. (PMID: 31166007) J Epidemiol Community Health. 2013 Dec 1;67(12):1075-6. (PMID: 23986491) Nicotine Tob Res. 2017 Feb;19(2):160-167. (PMID: 27613896) Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1795-1803. (PMID: 29127080) Curr Oncol. 2022 Nov 11;29(11):8579-8590. (PMID: 36421329) BMC Public Health. 2016 Mar 03;16:217. (PMID: 26941050) Addiction. 2020 Apr;115(4):757-767. (PMID: 31691397) BMC Public Health. 2022 Jul 12;22(1):1326. (PMID: 35820869) Nicotine Tob Res. 2017 Feb;19(2):176-182. (PMID: 27613880) Subst Abus. 2019;40(2):229-239. (PMID: 30924732) Addict Behav. 2019 Apr;91:95-101. (PMID: 30393015) Nicotine Tob Res. 2020 Apr 21;22(5):791-797. (PMID: 31403695) BMC Public Health. 2011 Oct 11;11:786. (PMID: 21989407) Intern Emerg Med. 2022 Mar;17(2):397-410. (PMID: 34435305) Addict Behav. 2019 Apr;91:45-50. (PMID: 30006020) Addict Sci Clin Pract. 2021 Jun 30;16(1):43. (PMID: 34193288) Nicotine Tob Res. 2019 Jan 1;21(1):119-126. (PMID: 29660034) N Engl J Med. 2019 Feb 14;380(7):629-637. (PMID: 30699054) Addiction. 2022 Sep;117(9):2493-2503. (PMID: 35491736) Clin Oral Investig. 2023 Sep;27(9):4911-4928. (PMID: 37526741) Cochrane Database Syst Rev. 2021 Jan 4;1:CD013229. (PMID: 33411338) Tob Control. 2023 Apr;32(e1):e3-e9. (PMID: 34789542) BMC Med. 2022 Aug 16;20(1):276. (PMID: 35971150) Eur Urol Oncol. 2021 Oct;4(5):766-783. (PMID: 32192941) Front Psychiatry. 2022 Aug 04;13:915946. (PMID: 35990084) Tob Control. 2010 Apr;19(2):98-103. (PMID: 20378585) Nicotine Tob Res. 2004 Dec;6(6):899-912. (PMID: 15801566) Sci Rep. 2022 Nov 30;12(1):20658. (PMID: 36450821) J Am Coll Cardiol. 2019 Dec 24;74(25):3112-3120. (PMID: 31740017) Int J Environ Res Public Health. 2017 Jul 18;14(7):. (PMID: 28718828) Respirology. 2020 Oct;25(10):1082-1089. (PMID: 32713105) Am J Public Health. 2015 Jun;105(6):1213-9. (PMID: 25880947) BMJ Open. 2021 Feb 22;11(2):e044222. (PMID: 33619197) BMJ Open. 2023 Jan 18;13(1):e064585. (PMID: 36657751) Tob Induc Dis. 2015 Mar 24;13(1):5. (PMID: 25814920) Addiction. 2023 Apr;118(4):634-645. (PMID: 36399154) B-ENT. 2016;12(1):17-21. (PMID: 27097389) Addiction. 2022 Apr;117(4):861-876. (PMID: 34636108) Cochrane Database Syst Rev. 2023 Sep 12;9:CD015226. (PMID: 37696529) Int J Environ Res Public Health. 2014 Oct 29;11(11):11220-48. (PMID: 25358095) Int J Environ Res Public Health. 2013 Jan 28;10(2):446-61. (PMID: 23358230) Int J Environ Res Public Health. 2022 Jun 17;19(12):. (PMID: 35742698) Addiction. 2023 Feb;118(2):382-386. (PMID: 36065820) Addiction. 2014 Mar;109(3):500-7. (PMID: 24345184) Nicotine Tob Res. 2015 Oct;17(10):1187-94. (PMID: 25896067) Recenti Prog Med. 2020 Jan;111(1):30-43. (PMID: 31992902) Health Educ Res. 2023 Mar 23;38(2):150-162. (PMID: 36727168) Addict Sci Clin Pract. 2022 Jan 6;17(1):2. (PMID: 34991693) Pharmacol Biochem Behav. 1993 Apr;44(4):891-900. (PMID: 8469698) Regul Toxicol Pharmacol. 2016 Nov 15;81 Suppl 1:S1-S14. (PMID: 27769828) Drug Alcohol Depend Rep. 2023 Mar 16;7:100143. (PMID: 37012981) J Am Board Fam Med. 2019 Jul-Aug;32(4):567-574. (PMID: 31300577) Lancet Public Health. 2021 Jul;6(7):e500-e509. (PMID: 34175001) BMJ Open. 2019 Feb 25;9(2):e023659. (PMID: 30808668) S Afr Med J. 2013 Sep 30;103(11):865-8. (PMID: 24148175) Trials. 2022 Sep 14;23(1):777. (PMID: 36104702) Trials. 2018 Aug 2;19(1):415. (PMID: 30071863) AIDS Care. 2020 Oct;32(10):1224-1228. (PMID: 31698920) Nicotine Tob Res. 2021 Feb 16;23(3):462-470. (PMID: 32770246) J Appl Behav Anal. 2019 Oct;52(4):928-943. (PMID: 31578724) BMJ Open. 2019 May 24;9(5):e028832. (PMID: 31129603) Addict Behav Rep. 2018 Dec 07;9:100151. (PMID: 31193745) N Engl J Med. 2020 Feb 20;382(8):766-772. (PMID: 31860794) Nicotine Tob Res. 2020 Aug 24;22(9):1524-1532. (PMID: 31828315) BMC Public Health. 2015 Oct 06;15:1026. (PMID: 26444980) Addiction. 2012 Aug;107(8):1493-500. (PMID: 22229871) Cochrane Database Syst Rev. 2023 May 5;5:CD006103. (PMID: 37142273) Psychopharmacology (Berl). 2017 Mar;234(5):773-779. (PMID: 28070620) Med J Aust. 2023 Apr 3;218(6):267-275. (PMID: 36939271) Int J Environ Res Public Health. 2019 Feb 28;16(5):. (PMID: 30823395) Tob Control. 2010 Feb;19(1):87-8. (PMID: 20154061) Nicotine Tob Res. 2022 Mar 1;24(4):555-563. (PMID: 34669956) BMJ Open. 2020 Sep 10;10(9):e037086. (PMID: 32912948) Behav Pharmacol. 2010 Mar;21(2):144-52. (PMID: 20168213) Am J Prev Med. 2013 Mar;44(3):207-15. (PMID: 23415116) Drug Alcohol Depend. 2023 Mar 1;244:109767. (PMID: 36638679) BMC Public Health. 2013 Mar 08;13:210. (PMID: 23496861) Addiction. 2018 Oct;113(10):1874-1882. (PMID: 29882257) Nicotine Tob Res. 2016 May;18(5):1157-62. (PMID: 26712843) Drug Alcohol Depend. 2023 Apr 1;245:109824. (PMID: 36857841) Int J Environ Res Public Health. 2021 Jan 07;18(2):. (PMID: 33430407) Addict Behav. 2021 Nov;122:107037. (PMID: 34284312) Addiction. 2022 Jul;117(7):2096-2107. (PMID: 35194862) Addict Behav. 2019 Dec;99:106105. (PMID: 31470240) Lancet Respir Med. 2020 Jan;8(1):54-64. (PMID: 31515173) Addiction. 2022 Jan;117(1):207-215. (PMID: 34105208) Addiction. 2022 Jan;117(1):224-233. (PMID: 34187081) Addict Behav. 2016 Jan;52:34-8. (PMID: 26348280) BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120) JAMA Intern Med. 2014 May;174(5):812-3. (PMID: 24664434) JAMA Netw Open. 2020 Jun 1;3(6):e206981. (PMID: 32539148) |
| معلومات مُعتمدة: | PRCPJT-NOV22/100012 United Kingdom CRUK_ Cancer Research UK |
| المشرفين على المادة: | 6M3C89ZY6R (Nicotine) |
| تواريخ الأحداث: | Date Created: 20240108 Date Completed: 20240109 Latest Revision: 20240404 |
| رمز التحديث: | 20240404 |
| مُعرف محوري في PubMed: | PMC10772980 |
| DOI: | 10.1002/14651858.CD010216.pub8 |
| PMID: | 38189560 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1469-493X |
|---|---|
| DOI: | 10.1002/14651858.CD010216.pub8 |